Action Against AMD has teamed-up with BenevolentAI to try and find a treatment and potential cure for age-related macular degeneration (AMD).
BenevolentAI, a company focused on the health benefits of developing artificial intelligence, will use its technology platform to ‘comprehensively review and understand the millions of scientific papers, clinical trials information, images, formulas, patents and additional data sets relating to AMD’.
Dr Jackie Hunter, CEO BenevolentBio, the bioscience subsidiary of BenevolentAI, said: ‘BenevolentAI’s deep learning linguistic models, knowledge graph and algorithms will be applied to create a better understanding of AMD, generate new insights and identify promising new research areas for treating this devastating condition.’